Prime Medicine, Inc. announced its third‑quarter 2025 earnings today, reporting results for the quarter ended September 30, 2025. The announcement came on November 7, 2025, and the company highlighted its financial performance for the period. Investors can find detailed financial figures on the company’s investor relations website.
Alongside the earnings release, Prime Medicine provided business updates, including new preclinical data for its PM577 candidate in Wilson’s Disease, which will be presented at the upcoming AASLD conference. The company also nominated PM647 as its development candidate for Alpha‑1 Antitrypsin Deficiency. Additionally, the company announced the appointment of Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer.
Prime Medicine also scheduled a virtual KOL event on November 12 to showcase its Wilson’s Disease strategy. The company reiterated its focus on advancing its liver‑targeted programs and its partnership with Bristol‑Myers Squibb for Prime‑Edited CAR‑T products. These updates underscore the company’s continued commitment to its strategic priorities and pipeline development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.